BiotechTube

SHR3680 + Placebo

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Conditions

Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Trial Timeline

Nov 1, 2021 → Oct 30, 2031

NCT ID
NCT05009290

About SHR3680 + Placebo

SHR3680 + Placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05009290. Target conditions include Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05009290Phase 3Recruiting

Competing Products

20 competing products in Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

See all competitors
ProductCompanyStageHype Score
R744 + R744Chugai PharmaceuticalPhase 3
77
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
77
R744 + Epoetin betaChugai PharmaceuticalPhase 3
77
R744 + R744Chugai PharmaceuticalPhase 3
77
R744 + R744Chugai PharmaceuticalPhase 3
77
R744Chugai PharmaceuticalPhase 3
77
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
41
FK949EAstellas PharmaPhase 1
33
roxadustatAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
ASP8825Astellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
ASP7991Astellas PharmaPhase 1
33
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
77
ATG-FAstellas PharmaApproved
85
CelecoxibAstellas PharmaPre-clinical
23
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
FK949EAstellas PharmaPhase 1
33

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85